# A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

> **NCT02978443** · PHASE2 · TERMINATED · sponsor: **Georgetown University** · enrollment: 14 (actual)

## Conditions studied

- Acral Lentiginous Melanoma
- Mucosal Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02978443
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-26
- **Primary completion:** 2020-07-28
- **Final completion:** 2022-08-02
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Lack of Enrollment
- **Last updated:** 2024-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02978443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02978443, "A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02978443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*